伊犁川宁生物技术股份有限公司关于全资子公司参与投资产业基金的进展公告

Group 1 - The company’s wholly-owned subsidiary, Yili Chuaning Investment Development Co., Ltd., plans to invest RMB 60 million in the Shanghai Lingang Qichuang Biotechnology Private Equity Fund, representing 7.50% of the total committed capital of RMB 800 million [1] - The fund's total committed capital has been reduced from RMB 800 million to RMB 565 million, increasing the company's stake from 7.50% to 10.62% [2] - The changes in the fund's structure are based on the current operational situation and are expected to help maintain stable operations of the fund [2] Group 2 - The fund has not yet completed the registration and filing process with the Asset Management Association of China, indicating some uncertainty in implementation [3] - The company will closely monitor the fund's progress and disclose updates in accordance with relevant regulations [3]